CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- 4 Open-market sale Director by Deputization sold 1,225,784 shares at an average $26.64 ($32,658,518)
- 4 Open-market sale President & CIO sold 339,441 shares at $26.47 ($8,985,003)
- 4 Shares withheld for taxes Director gave up 122 shares (to pay taxes)
- 4 Shares withheld for taxes Director gave up 124 shares (to pay taxes)
- 4 Shares withheld for taxes Director gave up 54 shares (to pay taxes)
- 4 Planned sale President & Immunovant CEO sold 200,000 shares at $21.92 ($4,384,000)
- 4 Open-market sale President & CIO sold 1,330,868 shares at an average $21.72 ($28,902,500)
- 4 Grant or award President and Vant Chair acquired 175,380 shares (grant or award)
- 4 Open-market sale CFO sold 406,731 shares at an average $22.43 ($9,122,307)
- 4 Open-market sale President & Immunovant CEO sold 275,000 shares at an average $22.47 ($6,179,750)
- 4 Shares withheld for taxes CFO gave up 2,129 shares (to pay taxes)
- 4 Open-market sale President & CIO sold 26,831 shares at $23.09 ($619,528)
- 4 Open-market sale Director sold 1,694,614 shares at an average $23.05 ($39,065,213)
- 4 Open-market sale Director sold 1,694,614 shares at an average $23.05 ($39,065,213)
- 4 Open-market sale Director by Deputization sold 1,694,614 shares at an average $23.05 ($39,065,213)
- 4 Open-market sale CEO sold 1,740,000 shares at $21.68 ($37,723,200)
- 4 Open-market sale 10% owner sold 3,103,745 shares at an average $21.89 ($67,942,352)
- 4 Open-market buy Director bought 16,666,666 shares at $21.00 ($349,999,986)
- 4 Planned sale President & Immunovant CEO sold 200,000 shares at $20.85 ($4,170,000)
- 4 Shares withheld for taxes CFO gave up 1,235 shares (to pay taxes)
Page 5 of 26 · 511 filings